Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Development and Multicenter Validation of an Explainable System for Neonatal ARDS-Compatible Phenotyping

2026. november 2. frissítette: Guangzhou Women and Children's Medical Center

Development and Multicenter Validation of an Explainable System for Identifying Clinical Phenotypes Compatible With Neonatal Acute Respiratory Distress Syndrome

Neonatal acute respiratory distress syndrome (NARDS) can be difficult to identify consistently because relevant information is distributed across clinical notes, imaging reports, and respiratory support records. This study will develop and validate an explainable system that organizes routinely collected electronic health record information and identifies infants whose clinical findings are compatible with NARDS.

The study will involve three neonatal intensive care units in China. Historical records from the lead center will be used for system development. A later period at the lead center and independent records from the two collaborating centers will be used for temporal and geographic validation. After the system has been locked, newly eligible infants will be included in a prospective validation phase without changing their clinical care.

System results will be compared with an independent reference assessment by neonatal intensive care specialists. The specialists will classify each infant's first eligible respiratory event as a high-likelihood NARDS-compatible clinical phenotype, a non-compatible clinical phenotype, clinically uncertain, or insufficient information. The study will evaluate sensitivity, specificity, predictive values, review workload, and the ability to identify insufficient information. During prospective validation, system results will remain unavailable to treating clinicians. The system is being evaluated as a research screening and review tool; it is not intended to replace a full clinical diagnosis or to determine treatment.

A tanulmány áttekintése

Állapot

Még nincs toborzás

Részletes leírás

Study design and objective This is a three-center observational cohort study combining retrospective system development and validation with prospective validation of a locked system. Its objective is to develop an explainable electronic health record-based system for identifying a NARDS-compatible clinical phenotype and prioritizing candidate records for specialist review.

Establishment of retrospective cohorts Historical NICU records dated January 1, 2018, through December 31, 2025, will provide the retrospective source population. Records from the lead center dated 2018-2022 will form the development cohort. Records from the lead center dated 2023-2025 will form an independent internal temporal validation cohort. Records from each collaborating center dated 2023-2025 will form two separate geographic external validation cohorts. The planned formal adjudication sample is approximately 1,600 candidate events for development and 800 candidate events in each of the three retrospective validation cohorts. Each infant's first eligible event will be used in the primary analysis.

Candidate screening and sampling Candidate records will be identified using prespecified evidence of respiratory support or escalation, bilateral or diffuse pulmonary imaging abnormalities, acute lung injury triggers, or relevant diagnostic expressions. Diagnostic codes will be used for screening and descriptive analyses.

System development and locking The system will extract traceable evidence from imaging reports and other permitted clinical records, including acute respiratory deterioration, acute lung injury triggers, pulmonary imaging abnormalities, and alternative explanations. It will assign high-priority review, routine review, or insufficient-information status and retain the supporting source and timestamp. The variable dictionary, text-processing rules, feature mappings, decision rules, thresholds, software version, and analysis plan will be locked before validation. No retraining, threshold selection, or center-specific tuning will use validation labels.

Reference standard Two qualified neonatal intensive care specialists will independently assess each evidence package using a prespecified adjudication manual. Disagreement will undergo independent arbitration and, when necessary, structured consensus. Adjudicators will be masked to system outputs, explanations, discharge diagnostic labels, and diagnostic codes. They will assign one of four categories: high-likelihood NARDS-compatible clinical phenotype, non-compatible clinical phenotype, clinically uncertain, or insufficient information. The high-likelihood phenotype requires an acute respiratory course, evidence of an acute lung injury trigger, bilateral or diffuse pulmonary parenchymal imaging abnormalities, and no single alternative explanation that fully accounts for the findings.

Prospective validation After retrospective temporal and geographic validation, the same locked system will be assessed in newly eligible infants at the participating centers. The proposed prospective phase will include consecutive eligible infants and will preserve the same index-event definition, evidence window, reference standard, and output categories. Results will be generated in silent mode and will not be displayed to treating clinicians or used to guide care. Independent adjudicators will remain masked to system outputs. Prospective sample size, center participation, recruitment dates, and consent arrangements will be finalized in the protocol and ethics documentation before this phase begins.

Performance analysis The primary measure will be sensitivity of high-priority review for the reference-standard high-likelihood phenotype in each independent validation cohort. Results will be presented separately for the lead-center temporal cohort, each external center, and the prospective phase, with center-specific prospective results when sample size permits. Ninety-five percent confidence intervals will accompany performance estimates. Sampling weights will be used when estimating performance in the historical candidate population. These categories will remain visible in study flow and sensitivity analyses. The primary analysis uses one event per infant.

Data governance Identifiable records, original free text, images, and identity linkage files will remain within each center's authorized environment. Locked code will preferentially be run locally at collaborating centers. Only approved aggregate results and the minimum permitted de-identified audit information will be transferred to the coordinating center. No research-specific treatment or additional biological sampling is planned.

Tanulmány típusa

Megfigyelő

Beiratkozás (Becsült)

1600

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi kapcsolat

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

Nem régebbi, mint 1 hónap (Gyermek)

Egészséges önkénteseket fogad

Nem

Tanulmányozható nemek

Összes

Mintavételi módszer

Nem valószínűségi minta

Tanulmányi populáció

Infants in NICU at 3 participating hospitals before 44 weeks' postmenstrual age whose records meet ≥1 prespecified screening criterion for possible acute pulmonary injury. Historical candidates are sampled from prespecified center/calendar strata. The prospective phase consecutively enrolls newly eligible infants after system locking and retrospective validation. Separately identified screen-negative infants are reviewed if included in the registered screening audit. TTN, RDS, PPHN, pneumonia, and pulmonary hemorrhage are not automatic exclusions by diagnosis alone. Independent adjudication determines whether an alternative condition fully explains findings. Missing key evidence yields an uncertain/insufficient-information assessment, not automatic exclusion or a negative disease label.

Leírás

Inclusion Criteria:

  1. Receiving care in the NICU of a participating hospital before 44 weeks of postmenstrual age at the index event.
  2. Meeting at least one prespecified candidate screening criterion, including a relevant acute lung injury or NARDS/ARDS expression, respiratory support or support escalation, bilateral or diffuse pulmonary parenchymal abnormalities in an imaging report, or a prespecified acute lung injury trigger.
  3. Having records within the prespecified center and calendar-period cohort, or being newly eligible during the approved prospective validation period.
  4. Availability of an appropriate legal basis for use of the records, including parental or guardian consent or an ethics-approved waiver when applicable.

Exclusion Criteria:

  1. Structural lung or airway malformations, complex congenital heart disease, or clearly established cardiac dysfunction or fluid overload that fully explains the respiratory failure and imaging abnormalities.
  2. Short-term postoperative mechanical ventilation without evidence of acute pulmonary injury.
  3. Duplicate or unresolvable records that prevent reliable identification of the infant or index event.

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Megfigyelési modellek: COHORT
  • Időperspektívák: OTHER

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Sensitivity of high-priority review for the high-likelihood NARDS-compatible clinical phenotype
Időkeret: One assessment per first eligible respiratory event, using records from 48 hours before to 48 hours after the first screening trigger (T0).

We will calculate the high-priority proportion among expert-adjudicated NARDS-compatible infants, excluding routine-review and insufficient-information outputs, and report performance with 95% CIs by cohort, with uncertain assessments reported separately.

One assessment per first eligible respiratory event, using records from 48 hours before to 48 hours after the first screening trigger (T0).

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Positive predictive value of high-priority review
Időkeret: One assessment per first eligible respiratory event, using records from 48 hours before to 48 hours after T0.

Among high-priority infants with determinate reference, report adjudicated high-likelihood NARDS-compatible proportion and 95% CI by cohort. Enriched samples yield sampling-weighted candidate estimates if permitted. It is not NICU-wide incidence.

One assessment per first eligible respiratory event, using records from 48 hours before to 48 hours after T0.
Negative predictive value for the high-priority triage policy
Időkeret: One assessment per first eligible respiratory event, using records from 48 hours before to 48 hours after T0.

Among determinate-reference non-high-priority infants, report non-compatible phenotype proportion and 95%CI by cohort; describe routine-review and insufficient-information outputs separately, to avoid concealment. Weight historical estimates if possible.

One assessment per first eligible respiratory event, using records from 48 hours before to 48 hours after T0.
Proportion of infants with a determinate reference-standard assessment
Időkeret: At reference adjudication of the first eligible event, using the same records from 48 hours before to 48 hours after T0.

Assessed infants with high-likelihood NARDS-compatible or non-compatible phenotype divided by all assessed; uncertain and insufficient-information assessments reported separately with reasons and 95% CIs, not relabeled negative or removed from flow.

At reference adjudication of the first eligible event, using the same records from 48 hours before to 48 hours after T0.

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Nyomozók

  • Tanulmányi szék: Liyuan Hu, Ph.D., Guangzhou Women and Children's Medical Center

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Becsült)

2026. november 10.

Elsődleges befejezés (Becsült)

2028. december 1.

A tanulmány befejezése (Becsült)

2028. december 1.

Tanulmányi regisztráció dátumai

Először benyújtva

2026. november 2.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2026. november 2.

Első közzététel (Tényleges)

2026. november 6.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. november 6.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. november 2.

Utolsó ellenőrzés

2026. november 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Egyéb vizsgálati azonosító számok

  • 2026-419A01

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Nem

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel